Amoxicillin

Placebo-controlled trials in young children with non-severe CAP found a clinical benefit for amoxicillin. Random-effects models found no strong evidence that amoxicillin differed from other antibiotics for clinical resolution. Clinical failure evidence for amoxicillin versus other antibiotics was unclear and did not exclude important benefit or harm. Adult amoxicillin regimens varied widely in duration and daily dose across studies. The review included 27 amoxicillin trials with 39,968 patients. WHO recommends amoxicillin as a first-choice antibiotic for mild or moderate bacterial CAP in adults and for non-severe pneumonia in children.